EASIVIRAL SIGNED
EASIVIRAL
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0EASIVIRAL project word cloud
Explore the words cloud of the EASIVIRAL project. It provides you a very rough idea of what is the project "EASIVIRAL" about.
Project "EASIVIRAL" data sheet
The following table provides information about the project.
| Coordinator |
ALTRATECH LIMITED
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | http://www.easiviral.com |
| Total cost | 2˙969˙000 € |
| EC max contribution | 2˙969˙000 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-12-01 to 2020-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ALTRATECH LIMITED | IE (LIMERICK) | coordinator | 2˙969˙000.00 |
Map
Project objective
In September 2016 WHO-Europe stated “Europe is at a critical point with HIV. New diagnoses in the European Region recently increased by 76%”. WHO urges “an accelerated people-centered response” based on taking HIV viral-load (VL) testing out of labs and into local clinics where it is most needed at point-of-care (PoC). No such solution exists today. New disruptive innovations are needed to address this. AltraTech Ltd has developed three proven biotechnologies to capture, purify, and detect the HIV virus from a blood sample, in 40 mins, using proven HIV biomarkers. This enables life-saving clinical intervention, immediate prescription and therapy for the patient, and stops further spread of the virus. The three techniques are innovative. Their combination, in a portable battery-operated kit format, is disruptive. It offers the unique combination of portability, robustness, reduced cost, with simultaneous increase in accuracy, combo-detection of Hepatitis and other viruses, and elimination of refrigerated reagents. It will address the above crisis, the HIV-VL PoC market, and has the potential to disrupt the €1B viral clinical diagnostics market and displace RT-PCR diagnostics that have been used in laboratories for two decades. Following a successful SME-Phase-1 feasibility, the technology received a Seal-of-Excellence in Phase-2(PHC-12-2015) – exceeded funding threshold. TRL improvements have been made in 2016, and a new CEO, management structure, and new venture funding significantly enhances AltraTech capacity to commercialise EASIVIRAL and see it reach market acceptance. The outcomes will enable capture a market leading share of > 30% of the €210M PoC HIV-VL market, reach cumulative EBITDA for this product alone of more than €18M by 2024. AltraTech will create 75 new jobs during this time, grow its portfolio of granted patents on its disruptive EASIVIRAL technology, and increase the revenues, jobs, and competitiveness of its manufacturing supply partners
Deliverables
| 1000 fabricated silicon sensor chips | Demonstrators, pilots, prototypes | 2020-02-12 16:28:30 |
| Poster showing lower-limit of quantification | Websites, patent fillings, videos etc. | 2020-02-12 16:28:31 |
| Data Sheets, App Notes, White Papers, Publicity material | Websites, patent fillings, videos etc. | 2020-01-30 10:06:41 |
Take a look to the deliverables list in detail: detailed list of EASIVIRAL deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EASIVIRAL" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EASIVIRAL" are provided by the European Opendata Portal: CORDIS opendata.